<p>亚利桑那州退休系统在第三季度购买了 Praxis Precision Medicines, Inc.（NASDAQ:PRAX - 免费报告）的新头寸，根据该公司在最近向证券交易委员会（SEC）提交的文件。该机构投资者购买了 5,417 股公司股票，价值约为 287,000 美元。</p>
<p>其他一些大型投资者最近也对该公司的头寸进行了调整。Nisa Investment Advisors LLC 在第二季度将其在 Praxis Precision Medicines 的头寸提高了 88.3%。Nisa Investment Advisors LLC 现在拥有 629 股公司股票，价值 26,000 美元，此前在上个季度又购买了 295 股。CWM LLC 在第二季度将其在 Praxis Precision Medicines 的股票头寸增加了 877.9%。CWM LLC 现在拥有 753 股公司股票，价值 32,000 美元，此前在此期间又购买了 676 股。Tower Research Capital LLC TRC 在第二季度将其在 Praxis Precision Medicines 的持股增加了 24.3%。Tower Research Capital LLC TRC 现在拥有 1,837 股公司股票，价值 77,000 美元，此前在此期间又购买了 359 股。Coastal Bridge Advisors LLC 在第三季度购买了 Praxis Precision Medicines 的一个新头寸，价值 204,000 美元。最后，VIRGINIA RETIREMENT SYSTEMS ET Al 在第三季度购买了 Praxis Precision Medicines 的一个新头寸，价值约 207,000 美元。67.84% 的股票由机构投资者持有。</p>
<h2>内部人员买卖</h2>
<p>在其他消息中，内部人员 Lauren Mastrocola 在 11 月 20 日星期四出售了 13,600 股该股票。股票以平均价格 192.08 美元出售，总交易额为 2,612,288.00 美元。出售后，该内部人员持有公司 10,442 股股票，价值 2,005,699.36 美元。这代表其持股减少了 56.57%。该交易在向 SEC 的文件中披露，相关信息可通过 SEC 网站获取。此外，首席法律顾问 Alex Nemiroff 在 11 月 20 日星期四出售了 25,130 股 Praxis Precision Medicines 的股票。该股票以平均价格 193.09 美元出售，总价值为 4,852,351.70 美元。出售完成后，首席法律顾问直接持有公司 20,832 股股票，价值约 4,022,450.88 美元。该交易使其持股减少了 54.68%。该出售的披露信息可在 SEC 文件中找到。公司内部人员持有公司 2.70% 的股票。</p>
<h2>分析师评级调整</h2>
<p>最近，一些分析师对 PRAX 股票发布了报告。瑞银集团在 12 月 15 日星期一的研究报告中将 Praxis Precision Medicines 的目标价设定为 750.00 美元。富国银行在 2 月 2 日星期一的研究报告中对 Praxis Precision Medicines 的股票进行了覆盖，给予 “持平” 评级，并设定目标价为 282.00 美元。德意志银行在 12 月 12 日星期五的研究报告中将 Praxis Precision Medicines 的目标价设定为 313.00 美元。BTIG Research 在 12 月 29 日星期一的研究报告中重申了 “买入” 评级，并将目标价上调至 843.00 美元（之前为 507.00 美元）。最后，Oppenheimer 在 12 月 15 日星期一的报告中重申了 “跑赢大盘” 评级，并将目标价上调至 750.00 美元（之前为 250.00 美元）。三位股票研究分析师对该股票给予了强烈买入评级，十二位给予了买入评级，一位给予了持有评级，两位给予了卖出评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “适度买入”，共识目标价为 536.06 美元。</p>
<p><strong>查看我们对 PRAX 的最新分析</strong></p>
<h2>Praxis Precision Medicines 股票表现</h2>
<p>PRAX 股票在周三开盘价为 320.48 美元。该公司 50 日移动平均价格为 287.32 美元，200 日移动平均价格为 164.66 美元。Praxis Precision Medicines, Inc.的 52 周低点为 26.70 美元，52 周高点为 328.60 美元。该公司的市值为 80.7 亿美元，市盈率为-24.84，贝塔值为 2.84。</p>
<h2>Praxis Precision Medicines 公司简介</h2>
<p>（免费报告）</p>
<p>Praxis Precision Medicines 是一家临床阶段的生物制药公司，专注于发现和开发针对神经兴奋性驱动的疾病的精准治疗。该公司应用转化神经科学和基因洞察，设计针对特定离子通道和受体亚型的小分子药物，这些通道和受体与神经和精神疾病相关。其研究旨在解决罕见癫痫、特发性震颤、难治性抑郁症及其他中枢神经系统（CNS）疾病的未满足需求。</p>
<p>该公司的产品管线包括多个处于不同开发阶段的主要候选药物。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过 Praxis Precision Medicines</li>
<li>Nvidia 首席执行官发布大胆的特斯拉预测</li>
<li>你的银行账户不再安全</li>
<li>在 2026 年 5 月之前购买这只黄金股票</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>黄金市场崩溃的那一天</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJBWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJBWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Praxis Precision Medicines 吗？</h2>
<p>在考虑投资 Praxis Precision Medicines 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Praxis Precision Medicines 并不在名单上。</p>
<p>虽然 Praxis Precision Medicines 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

基因改革 ETF - ARK

动态生物技术与基因组 ETF - Invesco

医药突破 ETF - ALPS

<p>亚利桑那州退休系统在第三季度收购了 5,417 股 Praxis Precision Medicines, Inc.（纳斯达克代码：PRAX），价值约为 287,000 美元。其他机构投资者也增加了他们的持股。内部人士的销售包括 Lauren Mastrocola 出售的 13,600 股和 Alex Nemiroff 出售的 25,130 股。分析师设定了不同的目标价格，其中瑞银集团为 750.00 美元，富国银行为 282.00 美元。PRAX 股票开盘价为 320.48 美元，市值为 80.7 亿美元，52 周价格区间为 26.70 美元至 328.60 美元</p>

<p>Arizona State Retirement System purchased a new position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 5,417 shares of the company's stock, valued at approximately $287,000.</p>
<div class="lb-trans"><p>亚利桑那州退休系统在第三季度购买了 Praxis Precision Medicines, Inc.（NASDAQ:PRAX - 免费报告）的新头寸，根据该公司在最近向证券交易委员会（SEC）提交的文件。该机构投资者购买了 5,417 股公司股票，价值约为 287,000 美元。</p>
</div><p>A number of other large investors have also recently made changes to their positions in the business. Nisa Investment Advisors LLC lifted its position in Praxis Precision Medicines by 88.3% in the 2nd quarter. Nisa Investment Advisors LLC now owns 629 shares of the company's stock valued at $26,000 after acquiring an additional 295 shares in the last quarter. CWM LLC grew its position in shares of Praxis Precision Medicines by 877.9% during the 2nd quarter. CWM LLC now owns 753 shares of the company's stock valued at $32,000 after acquiring an additional 676 shares during the period. Tower Research Capital LLC TRC grew its holdings in Praxis Precision Medicines by 24.3% during the second quarter. Tower Research Capital LLC TRC now owns 1,837 shares of the company's stock valued at $77,000 after purchasing an additional 359 shares during the period. Coastal Bridge Advisors LLC bought a new position in shares of Praxis Precision Medicines during the 3rd quarter worth $204,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in Praxis Precision Medicines during the third quarter worth about $207,000. 67.84% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>其他一些大型投资者最近也对该公司的头寸进行了调整。Nisa Investment Advisors LLC 在第二季度将其在 Praxis Precision Medicines 的头寸提高了 88.3%。Nisa Investment Advisors LLC 现在拥有 629 股公司股票，价值 26,000 美元，此前在上个季度又购买了 295 股。CWM LLC 在第二季度将其在 Praxis Precision Medicines 的股票头寸增加了 877.9%。CWM LLC 现在拥有 753 股公司股票，价值 32,000 美元，此前在此期间又购买了 676 股。Tower Research Capital LLC TRC 在第二季度将其在 Praxis Precision Medicines 的持股增加了 24.3%。Tower Research Capital LLC TRC 现在拥有 1,837 股公司股票，价值 77,000 美元，此前在此期间又购买了 359 股。Coastal Bridge Advisors LLC 在第三季度购买了 Praxis Precision Medicines 的一个新头寸，价值 204,000 美元。最后，VIRGINIA RETIREMENT SYSTEMS ET Al 在第三季度购买了 Praxis Precision Medicines 的一个新头寸，价值约 207,000 美元。67.84% 的股票由机构投资者持有。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部人员买卖</h2>
</div><p>In other news, insider Lauren Mastrocola sold 13,600 shares of the stock in a transaction that occurred on Thursday, November 20th. The shares were sold at an average price of $192.08, for a total transaction of $2,612,288.00. Following the sale, the insider owned 10,442 shares in the company, valued at $2,005,699.36. This represents a 56.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, General Counsel Alex Nemiroff sold 25,130 shares of Praxis Precision Medicines stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $193.09, for a total value of $4,852,351.70. Following the completion of the sale, the general counsel directly owned 20,832 shares of the company's stock, valued at approximately $4,022,450.88. The trade was a 54.68% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 2.70% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，内部人员 Lauren Mastrocola 在 11 月 20 日星期四出售了 13,600 股该股票。股票以平均价格 192.08 美元出售，总交易额为 2,612,288.00 美元。出售后，该内部人员持有公司 10,442 股股票，价值 2,005,699.36 美元。这代表其持股减少了 56.57%。该交易在向 SEC 的文件中披露，相关信息可通过 SEC 网站获取。此外，首席法律顾问 Alex Nemiroff 在 11 月 20 日星期四出售了 25,130 股 Praxis Precision Medicines 的股票。该股票以平均价格 193.09 美元出售，总价值为 4,852,351.70 美元。出售完成后，首席法律顾问直接持有公司 20,832 股股票，价值约 4,022,450.88 美元。该交易使其持股减少了 54.68%。该出售的披露信息可在 SEC 文件中找到。公司内部人员持有公司 2.70% 的股票。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级调整</h2>
</div><p>A number of analysts recently issued reports on PRAX shares. UBS Group set a $750.00 price objective on Praxis Precision Medicines in a research note on Monday, December 15th. Wells Fargo &amp; Company assumed coverage on shares of Praxis Precision Medicines in a research report on Monday, February 2nd. They set an &#34;equal weight&#34; rating and a $282.00 price objective on the stock. Deutsche Bank Aktiengesellschaft set a $313.00 target price on Praxis Precision Medicines in a research report on Friday, December 12th. BTIG Research reissued a &#34;buy&#34; rating and issued a $843.00 target price (up previously from $507.00) on shares of Praxis Precision Medicines in a research note on Monday, December 29th. Finally, Oppenheimer restated an &#34;outperform&#34; rating and set a $750.00 target price (up from $250.00) on shares of Praxis Precision Medicines in a report on Monday, December 15th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $536.06.</p>
<div class="lb-trans"><p>最近，一些分析师对 PRAX 股票发布了报告。瑞银集团在 12 月 15 日星期一的研究报告中将 Praxis Precision Medicines 的目标价设定为 750.00 美元。富国银行在 2 月 2 日星期一的研究报告中对 Praxis Precision Medicines 的股票进行了覆盖，给予 “持平” 评级，并设定目标价为 282.00 美元。德意志银行在 12 月 12 日星期五的研究报告中将 Praxis Precision Medicines 的目标价设定为 313.00 美元。BTIG Research 在 12 月 29 日星期一的研究报告中重申了 “买入” 评级，并将目标价上调至 843.00 美元（之前为 507.00 美元）。最后，Oppenheimer 在 12 月 15 日星期一的报告中重申了 “跑赢大盘” 评级，并将目标价上调至 750.00 美元（之前为 250.00 美元）。三位股票研究分析师对该股票给予了强烈买入评级，十二位给予了买入评级，一位给予了持有评级，两位给予了卖出评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “适度买入”，共识目标价为 536.06 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on PRAX</strong></p>
<div class="lb-trans"><p><strong>查看我们对 PRAX 的最新分析</strong></p>
</div><h2>Praxis Precision Medicines Stock Performance</h2>
<div class="lb-trans"><h2>Praxis Precision Medicines 股票表现</h2>
</div><p>PRAX stock opened at $320.48 on Wednesday. The firm has a 50 day moving average price of $287.32 and a 200-day moving average price of $164.66. Praxis Precision Medicines, Inc. has a 52-week low of $26.70 and a 52-week high of $328.60. The firm has a market capitalization of $8.07 billion, a price-to-earnings ratio of -24.84 and a beta of 2.84.</p>
<div class="lb-trans"><p>PRAX 股票在周三开盘价为 320.48 美元。该公司 50 日移动平均价格为 287.32 美元，200 日移动平均价格为 164.66 美元。Praxis Precision Medicines, Inc.的 52 周低点为 26.70 美元，52 周高点为 328.60 美元。该公司的市值为 80.7 亿美元，市盈率为-24.84，贝塔值为 2.84。</p>
</div><h2>Praxis Precision Medicines Profile</h2>
<div class="lb-trans"><h2>Praxis Precision Medicines 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing precision therapies for disorders driven by neuronal excitability. The company applies translational neuroscience and genetic insights to design small molecule drugs that target specific ion channels and receptor subtypes implicated in neurological and psychiatric conditions. Its research aims to address unmet needs in rare epilepsies, essential tremor, treatment-resistant depression and other central nervous system (CNS) disorders.</p>
<div class="lb-trans"><p>Praxis Precision Medicines 是一家临床阶段的生物制药公司，专注于发现和开发针对神经兴奋性驱动的疾病的精准治疗。该公司应用转化神经科学和基因洞察，设计针对特定离子通道和受体亚型的小分子药物，这些通道和受体与神经和精神疾病相关。其研究旨在解决罕见癫痫、特发性震颤、难治性抑郁症及其他中枢神经系统（CNS）疾病的未满足需求。</p>
</div><p>The company's pipeline includes several lead candidates at various stages of development.</p>
<div class="lb-trans"><p>该公司的产品管线包括多个处于不同开发阶段的主要候选药物。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Praxis Precision Medicines</li>
<li>Nvidia CEO Issues Bold Tesla Call</li>
<li>Your Bank Account Is No Longer Safe</li>
<li>Buy this Gold Stock Before May 2026</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
<li>The day the gold market broke</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Praxis Precision Medicines</li>
<li>Nvidia 首席执行官发布大胆的特斯拉预测</li>
<li>你的银行账户不再安全</li>
<li>在 2026 年 5 月之前购买这只黄金股票</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>黄金市场崩溃的那一天</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJBWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=PRAX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Praxis Precision Medicines Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Praxis Precision Medicines 吗？</h2>
</div><p>Before you consider Praxis Precision Medicines, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 Praxis Precision Medicines 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Praxis Precision Medicines wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Praxis Precision Medicines 并不在名单上。</p>
</div><p>While Praxis Precision Medicines currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Praxis Precision Medicines 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Arizona State Retirement System Purchases Shares of 5,417 Praxis Precision Medicines, Inc. $PRAX

Market Beat

生物科技 ETF - VanEck Vectors

Praxis Precision Medicines

医疗业 ETF - SPDR

2 倍做多纳斯达克生物技术 ETF - ProShares

标普生物技术 ETF - SPDR

纽交所高增长板生物技术指数 ETF - First Trust

医疗业 ETF - Vanguard

美国制药 ETF - iShares

亚利桑那州退休系统购入了 5,417 股 Praxis Precision Medicines, Inc. $PRAX 的股票